RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On February 10, 2017, RespireRx Pharmaceuticals Inc. (the
Company) announced that the Companys President and Chief
Executive Officer, James S. Manuso, Ph.D., will be presenting at
the BIO CEO Investor Conference 2017. Dr. Manuso is scheduled to
present at 1:00 p.m. Eastern Standard Time on Monday, February
13, 2017. The Conference is sponsored by the Biotechnology
Innovation Organization (BIO) and will be held at the Waldorf
Astoria Hotel, New York, New York on February 13 and 14, 2017.
The slide presentation that Dr. Manuso will be using at the
conference is attached as Exhibit 99.1 and is being furnished and
not filed to Item 7.01 of Form 8-K. The presentation will be
available by live webcast that can be accessed by clicking on the
investors tab on the Companys web-site (www.respirerx.com), and
following the links and instructions in the press release
announcing this presentation or by going to:
http://www.veracast.com/webcasts/bio/ceoinvestor2017/36118482417.cfm
The webcast replay will be available one hour after conclusion of
the live event and the replay will expire on May 15, 2017. The
press release announcing the Companys participation in the
conference is attached as Exhibit 99.2.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished and filed as part of this
report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by
reference.
About RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI)
RespireRx Pharmaceuticals Inc., formerly Cortex Pharmaceuticals, Inc., is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is focused on the clinical development in the areas of respiratory disorders, including respiratory depression and sleep apnea. It is engaged in research and clinical development of a class of compounds referred to as ampakines, which act to enhance the actions of the excitatory neurotransmitter glutamate at a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. Its ampakines, including CX717, CX1739 and CX1942, were efficacious in treating drug induced respiratory depression caused by opioids or certain anesthetics without offsetting the analgesic effects of the opioids or the anesthetic effects of the anesthetics. Its dronabinol is indicated for the treatment of sleep-related breathing disorders, including sleep apnea. RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) Recent Trading Information
RESPIRERX PHARMACEUTICALS INC. (OTCMKTS:RSPI) closed its last trading session 00.00 at 3.90 with 1,100 shares trading hands.
